Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2021

View Archived Issues

Researchers unveil ICE1 to be associated with arthrogryposis

H1R deficiency in mouse cholinergic neurons involved in schizophrenia negative symptom pathogenesis

Enrollment ongoing in phase I/II study of EXG-34217 in patients with bone marrow failure

Bristol Myers Squibb initiates phase II study of BMS-986012 in ES-SCLC

A new benzimidazole series of selective and potent inhibitors of long-chain acyl-CoA synthetase

Qpex begins enrollment in phase I study of oral beta-lactamase inhibitor QPX-7831

Phase I/II trial in Thailand studies COVID-19 vaccine candidate NDV-HXP-S

ZL-1201 demonstrates favorable antitumor activity and improved hematological safety profile in vivo

First patient dosed in phase Ib/IIa study SYN-004 in allogeneic HCT recipients

Initial phase III data for NT-300 tablets as treatment of mild or moderate COVID-19

FDA approves IND for phase I study of MLC-1501 in post-TBI recovery

Enrollment begins in phase II study of Pro-ocular in dry eye syndrome

LY-3484356 shows efficacy in ESR1 wild-type and mutant xenografts

Chungbuk National University, Cellgentek describe chimeric cytokine receptor compositions

Thyroid hormone receptor beta agonists discovered at Sunshine Lake Pharma

New NLRP3 agonists identified at Sichuan Kelun-Biotech Biopharmaceutical

Shanghai Sun-Sail Pharmaceutical Science & Technology patents antituberculosis compounds

Shenzhen Targetrx Biotechnology identifies mutant EGFR and HER2 inhibitors

Promising results for triple A1/A2A/A2B adenosine receptor antagonist in cancer immunotherapy

CDC7 inhibitor TQB-3824 shows promise in preclinical study

New target identified for treatment-resistant colorectal cancer

Moderna reports interim clinical data on RSV and CMV vaccine candidates

Bristol Myers Squibb presents first-in-class NLRP3 receptor agonists

New promising Johnson & Johnson cyclic HBV capsid assembly modulator series

New phase II trial evaluates pyridostigmine with ondansetron in myasthenia gravis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...